| Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation (NCT07739888) | Novartis Pharmaceuticals | 2027-12-30 |
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. (NCT07660172) | Novartis Pharmaceuticals | 2027-02-08 |
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. (NCT07679269) | Novartis Pharmaceuticals | 2027-01-01 |
| A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period (NCT07748624) | Novartis Pharmaceuticals | 2026-10-30 |
| A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients (NCT07767890) | Novartis Pharmaceuticals | 2026-10-30 |
| Pluvicto Real-world Investigation in Survival in Metastatic CRPC (NCT07697989) | Novartis Pharmaceuticals | 2026-10-15 |
| A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients (NCT07690319) | Novartis Pharmaceuticals | 2026-10-15 |
| A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients (NCT07770074) | Novartis Pharmaceuticals | 2026-10-08 |
| A Study to Assess the Safety of Subcutaneous Secukinumab for Treatment in Adult Indian Participants With Axial Spondyloarthritis (axSpA), Ankylosing Spondylitis (AS), and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) (NCT07737730) | Novartis Pharmaceuticals | 2026-09-30 |
| A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (NCT07681258) | Novartis Pharmaceuticals | 2026-09-30 |
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy (NCT07768371) | Novartis Pharmaceuticals | 2026-09-11 |
| A Study of Clinical Practice and Real-world Care of Patients Treated With mTOR, PI3K, and MEK Inhibitors for Extracranial Vascular Anomalies (NCT07767877) | Novartis Pharmaceuticals | 2026-08-31 |
| Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL (NCT07625306) | Novartis Pharmaceuticals | 2026-08-31 |
| A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait (NCT07454850) | Novartis Pharmaceuticals | 2026-08-30 |
| A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease (NCT07737743) | Novartis Pharmaceuticals | 2026-08-27 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN (NCT07498335) | Novartis Pharmaceuticals | 2026-08-26 |
| A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain (NCT07598448) | Novartis Pharmaceuticals | 2026-08-23 |
| A Real-World Medical Chart Review of Spinal Muscular Atrophy Patients Treated With Onasemnogene Abeparvovec in Saudi Arabia (NCT07737756) | Novartis Pharmaceuticals | 2026-08-20 |
| A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO) (NCT07700056) | Novartis Pharmaceuticals | 2026-08-14 |
| Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT) (NCT07642557) | Novartis Pharmaceuticals | 2026-08-04 |
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. (NCT05776927) | Novartis Pharmaceuticals | 2026-08-04 |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (NCT07421167) | Novartis Pharmaceuticals | 2026-08-04 |
| PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan (NCT07484269) | Novartis Pharmaceuticals | 2026-08-01 |
| A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates (NCT07465666) | Novartis Pharmaceuticals | 2026-08-01 |
| A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab (NCT07454889) | Novartis Pharmaceuticals | 2026-07-31 |
| A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR) (NCT07681271) | Novartis Pharmaceuticals | 2026-07-30 |
| Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden (NCT07621809) | Novartis Pharmaceuticals | 2026-07-16 |
| An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS (NCT07665437) | Novartis Pharmaceuticals | 2026-07-10 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) (NCT07387926) | Novartis Pharmaceuticals | 2026-07-05 |
| HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension (NCT07644364) | Novartis Pharmaceuticals | 2026-07-02 |
| ASsessing The REAl-world Safety & Effectiveness of Spinal Muscular Atrophy Participants Treated With Intrathecal Onasemnogene Abeparvovec-brve (OAV101B) (ITVISMA®): A U.S. Pragmatic Multicenter Study (STREAM) (NCT07448610) | Novartis Pharmaceuticals | 2026-07-01 |
| A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT07677254) | Novartis Pharmaceuticals | 2026-06-30 |
| A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan (NCT07677267) | Novartis Pharmaceuticals | 2026-06-30 |
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (NCT07570966) | Novartis Pharmaceuticals | 2026-06-30 |
| Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia (NCT07684469) | Novartis Pharmaceuticals | 2026-06-30 |
| Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (NCT06881823) | Novartis Pharmaceuticals | 2026-06-29 |
| Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab (NCT07039422) | Novartis Pharmaceuticals | 2026-06-26 |
| A Real-world Study of Treatment Patterns and Outcomes in Primary Immune Thrombocytopenia Patients Treated With Eltrombopag (NCT07587723) | Novartis Pharmaceuticals | 2026-06-25 |
| Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors (NCT07630961) | Novartis Pharmaceuticals | 2026-06-23 |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) (NCT07357727) | Novartis Pharmaceuticals | 2026-06-16 |
| Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors (NCT07660055) | Novartis Pharmaceuticals | 2026-06-16 |
| A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy (NCT07564401) | Novartis Pharmaceuticals | 2026-06-16 |
| A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy (NCT07416162) | Novartis Pharmaceuticals | 2026-06-15 |
| A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (NCT07635316) | Novartis Pharmaceuticals | 2026-06-12 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (NCT07340190) | Novartis Pharmaceuticals | 2026-06-12 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation (NCT07626281) | Novartis Pharmaceuticals | 2026-06-09 |
| Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments (NCT07468071) | Novartis Pharmaceuticals | 2026-06-08 |
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy (NCT07498426) | Novartis Pharmaceuticals | 2026-06-03 |
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis (NCT07604324) | Novartis Pharmaceuticals | 2026-06-02 |
| Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (NCT07489573) | Novartis Pharmaceuticals | 2026-06-01 |
| IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using Primary Data Collection (NCT07481084) | Novartis Pharmaceuticals | 2026-05-29 |
| A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (NCT07610278) | Novartis Pharmaceuticals | 2026-05-29 |
| Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer (NCT07604571) | Novartis Pharmaceuticals | 2026-05-28 |
| A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer (NCT07570979) | Novartis Pharmaceuticals | 2026-05-25 |
| A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome (NCT07598422) | Novartis Pharmaceuticals | 2026-05-13 |
| A Study of Ruxolitinib in Patients With Graft-Versus Host Disease (NCT07594587) | Novartis Pharmaceuticals | 2026-05-11 |
| An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) (NCT07517263) | Novartis Pharmaceuticals | 2026-05-11 |
| An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients. (NCT07543120) | Novartis Pharmaceuticals | 2026-05-07 |
| Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment (NCT07422610) | Novartis Pharmaceuticals | 2026-04-24 |
| A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany (NCT07549516) | Novartis Pharmaceuticals | 2026-04-17 |
| Remibrutinib Open Label Roll-over Post-trial Access Protocol (NCT07456891) | Novartis Pharmaceuticals | 2026-04-16 |
| Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis (NCT07340138) | Novartis Pharmaceuticals | 2026-04-15 |
| A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients (NCT07710716) | Novartis Pharmaceuticals | 2026-04-09 |
| A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab (NCT07543731) | Novartis Pharmaceuticals | 2026-04-02 |
| A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors (NCT07647042) | Novartis Pharmaceuticals | 2026-03-31 |
| Real World Adherence of PCSK9 Targeted Therapy (NCT07468500) | Novartis Pharmaceuticals | 2026-03-30 |
| A Study to Assess the Effects of Zigakibart on IgA Nephropathy. (NCT07146906) | Novartis Pharmaceuticals | 2026-03-26 |
| A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease (NCT07326709) | Novartis Pharmaceuticals | 2026-03-24 |
| A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy (NCT07378969) | Novartis Pharmaceuticals | 2026-03-23 |
| Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China (NCT07476170) | Novartis Pharmaceuticals | 2026-03-20 |
| A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction (NCT07465653) | Novartis Pharmaceuticals | 2026-03-18 |
| Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia (NCT07467993) | Novartis Pharmaceuticals | 2026-03-16 |
| A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients (NCT07517250) | Novartis Pharmaceuticals | 2026-03-15 |
| A Study of Treatment Patterns and Real-World Outcomes in IgA Nephropathy Patients in the United States (NCT07757048) | Novartis Pharmaceuticals | 2026-03-12 |
| A Real-World Study of Omalizumab Treatment Patterns in Chronic Urticaria Patients in China (NCT07450170) | Novartis Pharmaceuticals | 2026-03-10 |
| A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo (NCT07431177) | Novartis Pharmaceuticals | 2026-03-09 |
| A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT07441642) | Novartis Pharmaceuticals | 2026-03-09 |
| Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China (NCT07375355) | Novartis Pharmaceuticals | 2026-02-12 |
| Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) (NCT07290270) | Novartis Pharmaceuticals | 2026-02-04 |
| Remibrutinib in Real-world Clinical Practice - a US Sub-study (NCT07358780) | Novartis Pharmaceuticals | 2026-02-02 |
| Remibrutinib in Real-world Clinical Practice (NCT07358364) | Novartis Pharmaceuticals | 2026-02-02 |
| Clinical Outcomes of C3 Glomerulopathy and IC-MPGN in Russia: Hybrid Retrospective - Prospective Study (NCT06851845) | Novartis Pharmaceuticals | 2026-02-01 |
| A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan (NCT07465679) | Novartis Pharmaceuticals | 2026-01-28 |
| Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice (NCT06905301) | Novartis Pharmaceuticals | 2026-01-23 |
| A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab (NCT07504783) | Novartis Pharmaceuticals | 2026-01-22 |
| A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients (NCT07408219) | Novartis Pharmaceuticals | 2026-01-17 |
| REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria (NCT07229235) | Novartis Pharmaceuticals | 2026-01-13 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (NCT07190300) | Novartis Pharmaceuticals | 2026-01-13 |
| A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants (NCT07716410) | Novartis Pharmaceuticals | 2026-01-09 |
| CHART-C3G/CLNP023B12011 (NCT07331259) | Novartis Pharmaceuticals | 2026-01-01 |
| Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (NCT07288359) | Novartis Pharmaceuticals | 2025-12-29 |
| Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population (NCT07543419) | Novartis Pharmaceuticals | 2025-12-17 |
| Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters. (NCT07243002) | Novartis Pharmaceuticals | 2025-12-15 |
| Real-world Secukinumab Outcomes in Canadian HS Patients (NCT07282015) | Novartis Pharmaceuticals | 2025-12-12 |
| Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults (NCT07249463) | Novartis Pharmaceuticals | 2025-12-08 |
| A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC (NCT07226986) | Novartis Pharmaceuticals | 2025-12-05 |
| Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia (NCT06930859) | Novartis Pharmaceuticals | 2025-12-03 |
| A Study of DII235 in Adults With Elevated Lipoprotein(a) (NCT07235046) | Novartis Pharmaceuticals | 2025-12-02 |
| Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry. (NCT07190053) | Novartis Pharmaceuticals | 2025-12-01 |
| Impact of Implementation Strategies on Lp(a) Testing in Secondary Care Settings (NCT07508007) | Novartis Pharmaceuticals | 2025-11-28 |